|
Dr. Frank T. Gentile joined Hambrecht & Quist Capital Management in September 2002 as Vice President, Research; His emphasis is on the analysis of private and public companies in the fields of Functional Genomics and Proteomics, Cell and Gene Therapy, Oncology and Cardiovascular Disease. Previously Frank was Vice President, Technology Program Management at Millennium Pharmaceuticals. At Millennium, Frank was responsible for management of all technology platform development programs. Prior to joining Millennium, Dr. Gentile was Vice President of Product Development at Curis, Inc., a biotechnology company in Cambridge developing products in the area of Regenerative Medicine. From 1997 to 2000 he was Director and then Vice President, Program Management at Reprogenesis, Inc. From 1990-1997 he was employed at CytoTherapeutics, Inc, where he held several scientific and management positions.. Dr. Gentile received a B.E. degree in Chemical Engineering from The Cooper Union and a Ph.D. in Chemical Engineering from MIT. Prior to working in industry, he was a post-doctoral fellow at the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland. He is also an Adjunct Associate Professor of Biotechnology at Brown University. He has written over 120 peer reviewed publications and holds 30 US patents in the area of biotechnology. | 